Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation

Moshe Yeshurun*, Oren Pasvolsky, Liat Shargian, Dafna Yahav, Haim Ben-Zvi, Maly Rubinstein, Michal Sela-Navon, Ofir Wolach, Pia Raanani, Uri Rozovski

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Objectives: To assess the humoral immune response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation (HCT). Methods: This is a prospective cohort study.

Original languageEnglish
Pages (from-to)303.e1-303.e4
JournalClinical Microbiology and Infection
Volume28
Issue number2
DOIs
StatePublished - Feb 2022

Funding

FundersFunder number
Ministry of Health, State of Israel

    Keywords

    • Allogeneic haematopoietic cell transplantation
    • BNT162b2 vaccine
    • Graft-versus-host disease
    • Immunosuppression
    • SARS-CoV-2

    Fingerprint

    Dive into the research topics of 'Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation'. Together they form a unique fingerprint.

    Cite this